Stoke Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
STOK Nasdaq 2836 www.stoketherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Stoke Therapeutics, Inc.

Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating - Aug 21st, 2026 3:53 am
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Aug 18th, 2026 2:01 pm
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts - Aug 17th, 2026 6:01 pm
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript - Aug 10th, 2026 7:58 pm
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing? - Aug 7th, 2026 12:14 am
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Aug 5th, 2026 6:00 am
Stoke Therapeutics, Inc. Q2 2026 Earnings Call Summary - Aug 4th, 2026 6:30 am
Stoke Therapeutics Inc (STOK) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... - Aug 3rd, 2026 11:07 pm
Stoke Therapeutics Q2 Earnings Call Highlights - Aug 3rd, 2026 4:03 pm
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - Aug 3rd, 2026 3:10 pm
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates - Aug 3rd, 2026 2:01 pm
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates - Jul 27th, 2026 2:01 pm
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study - Jul 14th, 2026 8:04 am
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer - Jul 13th, 2026 5:30 am
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - Jun 30th, 2026 6:00 am
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Jun 4th, 2026 7:55 am
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates - Jun 1st, 2026 2:02 am